Amyloid neuropathies are important causes of progressive neuropathy and are increasingly treatable when recognized earlier. In this episode, Dr. Marcus Pinto reviews the major types of amyloid neuropathy, key diagnostic red flags, and the evolving treatment options for AL and hereditary ATTR amyloidosis. Learn how timely diagnosis can help prevent disease progression and improve patient outcomes. In this episode, Gordon Smith, MD, FAAN, speaks with Marcus V. Pinto, MD, MS, author of the article "Amyloid Neuropathies" in the Continuum® October 2026 Peripheral Nerve and Motor Neuron Disorders issue. Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Pinto is an assistant professor of neurology and medical director of the Nerve Pathology Laboratory at Mayo Clinic in Rochester, Minnesota. Additional Resources Read the article: Amyloid Neuropathies Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @GordonSmithMD Guest: @MarcusVPinto Full episode transcript available here Dr. Smith: One of the wonderful things about being a neurologist these days is the unbelievable therapeutic development, particularly for diseases that have been historically devastating for patients. I suspect many of you, like me, have found amyloidosis a sometimes confusing topic, but given the exciting therapeutic development for amyloid, it's a diagnosis that you really can't afford to miss if you're seeing patients with neuropathy. If you're interested in seeing order out of chaos and learning about amyloid in an organized way, and in particular, learning how to recognize patients who might benefit from these exciting new therapies, please keep listening. Dr. Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr. Smith: This is Dr. Gordon Smith. Today, I've got a real pleasure. I get to interview Dr. Marcus Pinto about his article on amyloid neuropathies. This article appears in the October 2026 Continuum issue on peripheral nerve and motor neuron disorders. Marcus, welcome to the Continuum Audio Podcast, and maybe you can start by introducing yourself to our audience. Dr. Pinto: Thank you, Dr. Smith. It's an honor for me to be here. So, my name is Marcus Pinto. I'm a peripheral nerve neurologist here at Mayo Clinic in Rochester. Dr. Smith: Marcus, it's a great article, and you're obviously a leader in the neuropathy field. I don't know that our listeners know what they're in for. This is super exciting. I always think back to medical school, and we used to joke that if you fall asleep during rounds and you wake up, just yell "amyloid," because it's a complicated enough topic that can mimic so many different things. And what's I think particularly exciting now is therapeutic development is really amazing. So many great stories, and I know our listeners are going to be very excited about that. But I wonder if you might begin with just a simple question. What is amyloid? Dr. Pinto: Yeah, so amyloid is an abnormal protein that misfolds in the blood and will deposit on tissues and causes usually mechanical or toxic damage to that organ. And as you said, it can affect the whole body. And it's very exciting now because the most common causes of amyloid neuropathy are treatable, which are AL amyloidosis and also hereditary ATTR amyloidosis. So, it's very exciting times for amyloid neuropathies. Dr. Smith: We are all hearing about amyloid now in the context of Alzheimer's disease or amyloid angiopathy. Can you kind of talk to us a little bit about just the relationship between these? Are they distinct entities, or are there some relationships that we should be aware of? Dr. Pinto: Yeah, I think that's very important to differentiate these disorders. So, whenever we talk about amyloidosis, you can have focal amyloidosis, which is Alzheimer's disease is a great example, or cerebro amyloid angiopathy. So, someone with CAA or someone with Alzheimer's disease, sometimes they occur together, they will only have amyloidosis in the brain. These are called focal amyloidosis. Can also, for example, happen in the eye sometimes and in other organs, and it's called focal amyloidosis. So, the disorders that we are talking about, talking about amyloid neuropathy, you're talking about systemic amyloidosis. So, diseases that will affect not only one organ, usually multiple organs, including the peripheral nerves, sensory motor, and autonomic. Dr. Smith: Are there focal neuropathic amyloid syndromes? Dr. Pinto: Yes. Very rarely, one can have something called an amyloidoma affecting a peripheral nerve, a single peripheral nerve, or a plexus, brachial, lumbosacral. Some of these patients, they will have a monoclonal gammopathy, but some of them, around 50% of them, do not have a monoclonal gammopathy, and you only identify the type of amyloidosis after a biopsy and doing mass spectrometry of the nerve. And all the reported cases so far of amyloidoma affecting the nerve, which is again a very rare disorder, are caused by light chain or AL amyloidosis, that even though the note is a systemic disorder, very rarely can also be focal. Dr. Smith: I think it's really helpful to have this framework of focal versus systemic amyloid, and I never really thought about Alzheimer's before as a focal amyloid syndrome. So, I think that's helpful in creating clarity in an area that has historically been confusing to a lot of us. There are a bunch of different forms of amyloid neuropathy. You've already mentioned light chain and hereditary amyloid neuropathy. What are the main forms that our listeners need to be familiar with? Dr. Pinto: So, I usually list 4 major types of amyloid neuropathy. So, the hereditary TTR, immunoglobulin light chain or AL amyloidosis, gelsolin amyloidosis, and a fourth one, which is wild-type ATTR. So, transthyretin, the protein, when deposits on tissue as amyloid, can be caused by a genetic form. So, these patients will have a pathogenic variant in the TTR gene, and there are other patients who will not have any abnormal variant in the TTR gene. And when we also do mass spec of the amyloid protein, it's normal transthyretin without any confirmation or any amino acid change, and these cases are called wild-type amyloidosis. Wild-type amyloidosis is considered an aging disorder, so it usually happens in men when they are older than 70 years old. It's like a nine to one ratio, male to female, and occur mostly in the elderly population. Dr. Smith: And wild-type typically causes cardiac manifestations, but we sometimes see neuropathy. Do you think that the neuropathies that we see in patients who have wild-type amyloid are amyloid-related, or do you think that they're just coincidental, just with aging? Dr. Pinto: That's a common question we get from our cardiology colleagues. I like to compare wild-type ATTR amyloidosis with one type of hereditary TTR amyloidosis. So, whenever talking about hereditary TTR, there is a strong genotypic phenotypic correlation. Okay? So, some specific variants cause more cardiomyopathy than neuropathy and vice versa. Some other variants usually cause both. There is one type of hereditary TTR, a variant of Val122Ile, or in the new classification, p.Val142Ile, that they present very similar to wild-type amyloidosis. So, these patients, they may have a peripheral neuropathy, and there's always a question. So, is it caused by wild-type amyloidosis? Is it caused by Val122Ile amyloidosis? So, the framework that I usually do is check for the comorbidities. Is the patient diabetic, obese, metabolic syndrome? Does the patient have any other cause for neuropathy? Because usually most of these cases with wild-type ATTR or Val122Ile hereditary TTR with cardiomyopathy that have neuropathy, the neuropathy is caused by another disorder, and it's not caused by the amyloid. However, rarely in clinic, we see patients who do have a progressive neuropathy, usually more of a slowly progressive neuropathy, and have wild-type TTR amyloidosis, and you can't find other cause for neuropathy. So, in these cases, and I have done that, that I have even have done nerve biopsies on these patients and even not finding the wild-type TTR amyloid in the nerve, that I've told the cardiologist, "Hey, I've done my homework here. I did not find any other cause of neuropathy." I've seen this patient after 6 months, one year, and this neuropathy is slowly progressing. It doesn't look like a hereditary neuropathy, like a CMT. Doesn't sound like idiopathic neuropathy because there are weakness, it's progressive. The idiopathic neuropathy usually when progresses very, very slowly. So that I have attributed the neuropathy to wild-type. Dr. Smith: I think we probably should pivot here, Marcus, and spend most of our time talking about light chain and hereditary ATTR. But I think this is a topic that we come across all the time, at least where I practice. We take care of a large population of African Americans. As you know, the Val122Ile mutation is very common in that population, and we have to kind of take that fish off the hook and figure out. And there's obviously been a lot of therapeutic development in cardiac amyloid as well, and our listeners sh